Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes
- 1 March 2019
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 21 (3) , 110-118
Abstract
Hybrid closed-loop (HCL) systems combine continuous glucose monitoring with continuous subcutaneous insulin infusion (CSII) to continuously self-adjust basal insulin delivery. Relative to CSII, HCL improves glycemic control and reduces the risk of hypoglycemia but has higher acquisition costs. The aim of this analysis was to assess the cost-effectiveness of the MiniMed™ 670G HCL system versus CSII in people with type 1 diabetes (T1D) in Sweden. Cost-effectiveness analysis, from a societal perspective, was performed over patient lifetimes using the IQVIA CORE Diabetes Model. Clinical data were sourced from a study comparing the MiniMed 670G system with CSII in people with T1D. Cost data, expressed in 2018 Swedish krona (SEK), were obtained from Swedish reference prices and published literature. The MiniMed 670G system was associated with a quality-adjusted life-year (QALY) gain of 1.90 but higher overall costs versus CSII, leading to an incremental cost-effectiveness ratio (ICER) of SEK 164,236 per QALY gained. Use of the HCL system resulted in a lower cumulative incidence of diabetes-related complications. Higher HCL system acquisition costs were partially offset by reduced complication costs and productivity losses. In people with T1D poorly controlled at baseline, the MiniMed 670G system was associated with 2.25 incremental QALYs versus CSII, yielding an ICER of SEK 15,830 per QALY gained. The MiniMed 670G system was associated with clinical benefits and quality-of-life improvements in people with T1D relative to CSII. At a willingness-to-pay threshold of SEK 300,000 per QALY gained, this HCL system likely represents a cost-effective treatment option for people with T1D in Sweden.Keywords
This publication has 56 references indexed in Scilit:
- 6. Glycemic Targets: Standards of Medical Care in Diabetes—2019Diabetes Care, 2018
- Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort studyThe Lancet, 2018
- Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in SwedenBMJ Open Diabetes Research & Care, 2017
- An Overview of Insulin Pumps and Glucose Sensors for the GeneralistJournal of Clinical Medicine, 2016
- Diabetes Prevalence in Sweden at Present and Projections for Year 2050PLOS ONE, 2015
- Intensive Diabetes Therapy and Ocular Surgery in Type 1 DiabetesNew England Journal of Medicine, 2015
- Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in SwedenDiabetes Care, 2014
- Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic HypoglycemiaDiabetes, 2014
- Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 DiabetesNew England Journal of Medicine, 2010
- Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years' DurationArchives of internal medicine (1960), 2009